Arne Hansen received his MD at the University of Hamburg. After clinical training and a 3-year PostDoc at NIH he joined the Department for Experimental Pharmacology and Toxicology at UKE/Hamburg in 2007 and was appointed as Assistant Professor in 2012. His research focus is the development of 3D cell culture models to study cardiomyocyte biology and disease. In this context, he has developed techniques to generate heart tissues from human CRISPR/Cas9 engineered iPSCs -and optimized test systems to analyze contractile force and calcium transients with high levels of automation. In 2015 he founded the spin-off EHT Technologies.